ライフサイエンスコーパス: iopamidol

1 istration of a pH-responsive contrast agent (iopamidol).

2 7) or manual injection (n = 73) of 150 mL of iopamidol.

3 e margin of safety is enhanced by the use of iopamidol.

4 pathway was proposed for the degradation of iopamidol.

5 ctions during period 1 (10,831 injections of iopamidol 300 and 1851 injections of iopamidol 370) and

6 and 12,138 injections (10, 064 injections of iopamidol 300 and 2074 injections of iopamidol 370) duri

7 se event rates for intravenous injections of iopamidol 300 of less than 6 mL/sec but is associated wi

8 Adverse event rates for iopamidol 300 were not affected by extrinsic warming (ex

9 vasation and overall adverse event rates for iopamidol 370 (extravasation rates: 0.27% [five of 1851]

10 ions of iopamidol 300 and 1851 injections of iopamidol 370) and 12,138 injections (10, 064 injections

11 ions of iopamidol 300 and 2074 injections of iopamidol 370) during period 2.

12 all adverse event rates for the more viscous iopamidol 370.

13 nts who underwent pulmonary angiography with iopamidol 76% were retrospectively reviewed.

14 treatment of iopromide, the potential TPs of iopamidol (a structurally similar compound to iopromide)

15 n-cardiogenic pulmonary oedema, after use of iopamidol, a widely used, low osmolar, non-ionic, radiog

16 Protocol included 150 mL oral iopamidol administered at 3 mL/sec.

17 t-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 ver

18 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (

19 L occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol

20 nter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney

21 -osmolar contrast media (ioxaglate, iohexol, iopamidol, and ioversol) were compared.

22 ne was released during the transformation of iopamidol, and was mainly oxidized to iodate.

23 obitridol, an X-ray contrast agent analog of iopamidol but containing a single set of amide protons,

24 h 300 and 370 mg of iodine per milliliter of iopamidol by using a mechanical injector at increasing f

25 owed by contrast material-enhanced (80 mL of iopamidol) computed tomography (CT) of the chest, abdome

26 bolus of 3 mL/kg per hour for 1 hour before iopamidol contrast, followed by an infusion of 1 mL/kg p

27 ine and after administration of iodixanol or iopamidol contrast.

28 ore to 72 hours after each administration of iopamidol during a computed tomographic examination perf

29 related to the intravenous administration of iopamidol during CT examinations occurring 200 days befo

30 increase in the creatinine level; the use of iopamidol effected a relatively small rise in creatinine

31 Chlorination of iopamidol followed a second order reaction, with an obse

32 toxicity tests indicate that chlorination of iopamidol generates a toxic mixture of high molecular we

33 Standard protocol involved 125 mL of iopamidol injected at 4 mL/sec.

34 obtained 20 and 70 seconds after intravenous iopamidol injection.

35 of the iodinated X-ray contrast media (ICM) iopamidol, iopromide, iohexol, iomeprol, and diatrizoate

36 Iopamidol nephrotoxicity was negligible in this cohort o

37 nt after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or wi

38 , use of foscarnet (P =.003), and receipt of iopamidol (P =.073) each prompted a rise in serum creati

39 After intravenous injection of 100 mL iopamidol, the woman became short of breath, and a chest

40 LC-QToF-MS revealed the presence of two iopamidol TPs in unspiked AOP-treated wastewater.

41 n iopromide TPs was applied to the predicted iopamidol TPs.

42 In the presence of aqueous chlorine, only iopamidol was transformed.

43 er generate more pressure than injections of iopamidol with 300 mg of iodine per milliliter at the sa

44 Hand injection of iopamidol with 300 mg of iodine per milliliter generated

45 Injections of iopamidol with 370 mg of iodine per milliliter generate

46 bility of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast mediu